Nghiên cứu giá trị thang điểm LIRADS bản 2018 trên CLVT trong đánh giá đáp ứng điều trị của ung thư biểu mô tế bào gan sau nút mạch bằng hạt vi cầu lần đầu

Abstract

Backround: In HCC, locoregional therapy (LRT) included transarterial chemotheraphy embolisation- TACE is performed as a bridging or downstaging treatment, improved overall survival, or a curative treatment. Liver Imaging Reporting and Data Systems (LI-RADS) Treatment Response was created to evaluate each lesion post TACE, which has localized and suitable for determine whether the tumor is still viable or non-viable.

Purpose: To evaluate the aplication of the Liver Imaging Reporting and Data System (LI-RADS) treatment response algorithm (LR-TR) on CT in patient post-treatment evaluation following drug-eluting beads transarterial chemoembolization (DEB-TACE) for hepatocellular carcinoma (HCC).

Material and Methods: Between 6/2021 and 9/2022, a prospective and retrospective cross-sectional study involved 29 patients with hepatocellular carcinomar (HCC) underwent treatment base drug-eluting beads transarterial chemoembolization (DEB-TACE). The clinical situation, AFP levels and Computer tomography of patient in post treatment were analysed.

Results: a total of 29 patients with median age was 61,3 ± 11.03 years old, male: female was 13.5/1. After first - line Deb-TACE: the performance status response in patient were inprovement in 28/29 patient, AFP response in 31%, LR-TR non-viable in 13 (44.8%) of 29 patients. The performance status response- AFP response- imaging response correlation were not statistically different with p= 0.552 and p=0.647. 

Conclusion: Using CT LR-TR to evaluate of  HCC post Deb-TACE was an easy-to-use means, suitable for clinical practice, and useful for vascular interventionalist.